Wider payer coverage could give GLP-1 revolution a jolt

However, payers aren’t likely to begin putting these GLP-1 treatments on formulary right away, drug policy experts caution.

Related Keywords

California ,United States ,San Diego ,Inmaculada Hernandez ,Madrigal Pharma Rezdiffra ,Novo Saxenda ,Jeff Levin Scherz ,Drug Administration ,Leonardd Schaeffer Center ,Morgan Health ,Medicaid Services ,Uc San Diego Skaggs School Of Pharmacy ,Linkedin ,Centers For Medicare ,Health Policy Economics ,University Of California ,Novo Nordisk ,Goldman Sachs ,Congressional Budget Office ,New England Journal ,Medicare Advantage ,Diego Skaggs School ,Pharmaceutical Sciences ,Health Policy ,Madrigal Pharma ,